PRIFTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Priftin, and what generic alternatives are available?
Priftin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in PRIFTIN is rifapentine. Three suppliers are listed for this compound. Additional details are available on the rifapentine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRIFTIN?
- What are the global sales for PRIFTIN?
- What is Average Wholesale Price for PRIFTIN?
Summary for PRIFTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 33 |
| Clinical Trials: | 11 |
| Patent Applications: | 2,988 |
| Drug Prices: | Drug price information for PRIFTIN |
| What excipients (inactive ingredients) are in PRIFTIN? | PRIFTIN excipients list |
| DailyMed Link: | PRIFTIN at DailyMed |
Recent Clinical Trials for PRIFTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Taiwan University | Phase 3 |
| Kaohsiung Veterans General Hospital. | Phase 3 |
| Chang Gung Memorial Hospital | Phase 3 |
Pharmacology for PRIFTIN
| Drug Class | Rifamycin Antimycobacterial |
US Patents and Regulatory Information for PRIFTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PRIFTIN | rifapentine | TABLET;ORAL | 021024-001 | Jun 22, 1998 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
